JP Morgan Chase
BCAX

JP Morgan Chase’s Bicara Therapeutics BCAX Stock Holding History

JP Morgan Chase’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.8M Buy
1,015,965
+838,557
+473% +$18.7M ﹤0.01% 1889
2026
Q1 		$3.38M Buy
177,408
+160,561
+953% +$2.76M ﹤0.01% 3682
2025
Q4 		$284K Sell
16,847
-8,088
-32% -$138K ﹤0.01% 5347
2025
Q3 		$394K Sell
24,935
-2,523
-9% -$28.2K ﹤0.01% 5166
2025
Q2 		$255K Buy
27,458
+5,664
+26% +$67.5K ﹤0.01% 5119
2025
Q1 		$284K Sell
21,794
-42,946
-66% -$570K ﹤0.01% 5082
2024
Q4 		$1.13M Buy
64,740
+64,010
+8,768% +$1.33M ﹤0.01% 4549
2024
Q3 		$18.6K Buy
+730
New +$18.6K ﹤0.01% 6250

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase's BCAX Position: Q2 2026 in Review

JP Morgan Chase increased its Bicara Therapeutics (BCAX) stake by 473% in Q2 2026, buying an estimated $18.7M and bringing the position to 1,015,965 shares worth $29.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1889.

JP Morgan Chase first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • JP Morgan Chase held 1,015,965 shares of Bicara Therapeutics worth $29.8M as of Q2 2026.
  • JP Morgan Chase bought 838,557 Bicara Therapeutics shares in Q2 2026, an estimated $18.7M.
  • Bicara Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1889 holding.
  • JP Morgan Chase first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.